SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

CARDEMIL, Felipe  y  DELANO, Paul H. Merlina y nuevos tratamientos de schwannomas vestibulares en pacientes con neurofibromatosis tipo 2. Rev. Otorrinolaringol. Cir. Cabeza Cuello [online]. 2012, vol.72, n.2, pp. 195-202. ISSN 0718-4816.  http://dx.doi.org/10.4067/S0718-48162012000200015.

    1. Hanemann CO. Magic but treatable? Tumours due to loss of Merlin. Brain 2008; 131: 606-15. [ Links ]

    2. Lalwani AK. Current Diagnosis and treatment in Otolaryngology - Head and Neck Surgery. Fourth Edition, 2008, McGraw-Hill. [ Links ]

    3. Theodosopoulos PV, Pensak ML. Contemporary Management of Acoustic Neuromas. Laryngoscope 2011; 121: 1133-7. [ Links ]

    4. Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 2006; 66: 730-2. [ Links ]

    5. MacCollin M, Chiocca EA, Evans DG, y cols. Diagnostic criteria for schwannomatosis. Neurology 2005; 64: 1838-45. [ Links ]

    6. Ho SY, Kveton JF. Acoustic neuroma. Assessment and management. Otolaryngol Clin North Am 2002; 35: 393-404. [ Links ]

    7. Zernotti ME, Ojeda A, Zernotti M. Schwannomas intrapetrosos del nervio facial. Acta Otorrinolaringol Esp 2005; 56: 434-7. [ Links ]

    8. Celedón C, Pardo J, Abarca A, Delano PH. Schwannomas no vestibulares de cabeza y cuello: Presentación de 6 casos clínicos. Rev Otorrinolaringol Cir Cabeza Cuello 2011; 71: 44-52. [ Links ]

    9. Stott C, Albertz N, Aedo C. Neurinoma del acústico (schwanoma vestibular): Revisión y actualización de la literatura. Rev Otorrinolaringol Cir Cabeza Cuello 2008; 68: 301-8. [ Links ]

    10. Ammoun S, Hanemann CO. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nat Rev Neurol 2011; 7: 392-9. [ Links ]

    11. Kalamarides M, Niwa-Kawakita M, Leblois H, y cols. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16: 1060-5. [ Links ]

    12. Schulze KM, Hanemann CO, Muller HW, Hanenberg H. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 2002; 11: 69-76. [ Links ]

    13. Flaiz C, Kaempchen K, Matthies C, Hanemann CO. Actin-rich protrusions and non localized GTPase activation in Merlin-deficient schwannomas. J Neuropathol Exp Neurol 2007; 66: 608-16. [ Links ]

    14. Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 2005; 63: 75-81. [ Links ]

    15. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile eplatforms for cancer immunotherapy. Nature Reviews Immunology 2010; 10: 317-27. [ Links ]

    16. Plotkin SR, Halpin C, Blakeley JO, Slattery WH 3rd, Welling DB, Chang SM y cols. Suggested response criteriaforphase II antitumor drug studiesfor neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009; 93: 61-77. [ Links ]

    17. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. [ Links ]

    18. Plotkin SR, Stemmer-Rachaminov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A y cols. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361: 358-67. [ Links ]

    19. Guntinas-Lichius O. Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med 2009 ; 361: 1809-10; authorreply 1810-1. [ Links ]

    20. Diao JS, Xia WS, Guo AZ. Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med 2009; 361: 1810; authorreply 1810-1. [ Links ]

    21. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C y cols. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010; 12: 14-8. [ Links ]

    22. Mautner VF, Nguyen R, Knecht R, Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and reboundafter drug discontinuation. Ann Oncol 2010; 21:2294-5. [ Links ]

    23. An MM, Zou Ζ, Shen H, Liu P, Chen ML, Cao YB y cols. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010; 66: 813-21. [ Links ]

    24. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR y cols. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neuro-fibromatosis-related tumors. Cancer Res 2010; 70: 3483-93. [ Links ]

    25. Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011; 22: 990-1. [ Links ]

    26. Eminowicz GK, Raman R, Conibear J, Plowman PN. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 2012; 126: 79-82. [ Links ]

    27. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG 2nd. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010; 31: 1135-43. [ Links ]

    28. Clark JJ, Provenzano M, Diggelmenn HR, Xu N, Hansen SS, Hansen MR. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. OtolNeurotol 2008; 29: 846-53. [ Links ]

    29. Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, y cols. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology 2010; 12: 834-43. [ Links ]

    30. Saydam O, Senol O, Würdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, y cols. miRNA-7 Attenuation in Schwannoma Tumors Stimulates Growth by Upregulating Three Oncogenic Signaling Pathways. Cancer Res 2011; 71: 852-61. [ Links ]

    31. Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett 2012; 586: 1403-8. [ Links ]